Rxivist logo

One-Step Rapid Quantification of Serum Neutralizing Antibody after COVID-19 Vaccination by a High-Throughput Nanoplasmonic Sensor Platform

By Liping Huang, Ying Li, Changyou Luo, Nadia Touil, Hicham el Annaz, Youqian Cheng, Shaoqi Zeng, Tang Dang, Jiawei Liang, Wenjun Hu, Hao Xu, Jiasheng Tu, Yan Shen, Gang L. Liu

Posted 27 Apr 2021
medRxiv DOI: 10.1101/2021.04.21.21255838

The COVID-19 vaccination efficacy depends on serum production level of the neutralizing IgG antibody (NA) specific to the receptor binding domain of SARS-Cov-2 spike protein. Therefore, a high-throughput rapid assay to measure the total SARS-CoV-2 NA level is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, vaccine development, and assessment. Here, we developed a nanoplasmonic immunosorbent assay (NanoPISA) platform for one-step rapid quantification of SARS-CoV-2 NAs in clinical serum samples for high-throughput evaluation of COVID-19 vaccine effectiveness. The NanoPISA platform enhanced by the use of nanoporous hollow gold nanoparticle coupling was able to detect SARS-CoV-2 NAs with a limit of detection of 0.1 ng/mL within 15 min. The one-step NanoPISA for SARS-CoV-2 NA detection in clinical specimens yielded good results, comparable to those obtained in the gold standard seroneutralization test and the surrogate virus neutralizing ELISA. Collectively, our findings indicate that the one-step NanoPISA may offer a rapid and high-throughput NA quantification platform for evaluating the effectiveness of COVID-19 vaccines.

Download data

  • Downloaded 247 times
  • Download rankings, all-time:
    • Site-wide: 121,565
    • In infectious diseases: 5,169
  • Year to date:
    • Site-wide: 35,274
  • Since beginning of last month:
    • Site-wide: 40,941

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide